Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
CDXS's Cash to Debt is ranked higher than
81% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. CDXS: No Debt )
CDXS' s 10-Year Cash to Debt Range
Min: 2.71   Max: No Debt
Current: No Debt

Equity to Asset 0.65
CDXS's Equity to Asset is ranked higher than
72% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CDXS: 0.65 )
CDXS' s 10-Year Equity to Asset Range
Min: -1.82   Max: 0.79
Current: 0.65

-1.82
0.79
F-Score: 4
Z-Score: -6.61
M-Score: -2.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -126.78
CDXS's Operating margin (%) is ranked higher than
67% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. CDXS: -126.78 )
CDXS' s 10-Year Operating margin (%) Range
Min: -155.16   Max: -6.65
Current: -126.78

-155.16
-6.65
Net-margin (%) -125.15
CDXS's Net-margin (%) is ranked higher than
67% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. CDXS: -125.15 )
CDXS' s 10-Year Net-margin (%) Range
Min: -153.96   Max: -7.97
Current: -125.15

-153.96
-7.97
ROE (%) -115.69
CDXS's ROE (%) is ranked higher than
55% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. CDXS: -115.69 )
CDXS' s 10-Year ROE (%) Range
Min: -99.57   Max: -7.96
Current: -115.69

-99.57
-7.96
ROA (%) -75.00
CDXS's ROA (%) is ranked higher than
55% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. CDXS: -75.00 )
CDXS' s 10-Year ROA (%) Range
Min: -70.2   Max: -6.04
Current: -75

-70.2
-6.04
ROC (Joel Greenblatt) (%) -708.26
CDXS's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. CDXS: -708.26 )
CDXS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -487.17   Max: -33.21
Current: -708.26

-487.17
-33.21
Revenue Growth (%) -42.40
CDXS's Revenue Growth (%) is ranked higher than
60% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CDXS: -42.40 )
CDXS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -42.4
Current: -42.4

EPS Growth (%) 45.60
CDXS's EPS Growth (%) is ranked higher than
96% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. CDXS: 45.60 )
CDXS' s 10-Year EPS Growth (%) Range
Min: 0   Max: 45.6
Current: 45.6

0
45.6
» CDXS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CDXS Guru Trades in Q3 2013

Jim Simons 84,100 sh (-47.07%)
» More
Q4 2013

CDXS Guru Trades in Q4 2013

Jim Simons 246,943 sh (+193.63%)
» More
Q1 2014

CDXS Guru Trades in Q1 2014

Jim Simons 196,292 sh (-20.51%)
» More
Q2 2014

CDXS Guru Trades in Q2 2014

Jim Simons 209,000 sh (+6.47%)
» More
» Details

Insider Trades

Latest Guru Trades with CDXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-12-31 Sold Out 0.0012%$4.24 - $6.02 $ 2.3-12%0
George Soros 2011-09-30 New Buy$4.39 - $10.24 $ 2.3-67%14800
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.00
CDXS's P/B is ranked higher than
84% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. CDXS: 3.00 )
CDXS' s 10-Year P/B Range
Min: 0.83   Max: 3.96
Current: 3

0.83
3.96
P/S 3.30
CDXS's P/S is ranked higher than
90% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. CDXS: 3.30 )
CDXS' s 10-Year P/S Range
Min: 0.27   Max: 3.88
Current: 3.3

0.27
3.88
EV-to-EBIT -1.82
CDXS's EV-to-EBIT is ranked higher than
53% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CDXS: -1.82 )
CDXS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -1.82

Current Ratio 2.49
CDXS's Current Ratio is ranked higher than
64% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. CDXS: 2.49 )
CDXS' s 10-Year Current Ratio Range
Min: 1.14   Max: 3.98
Current: 2.49

1.14
3.98
Quick Ratio 2.31
CDXS's Quick Ratio is ranked higher than
65% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. CDXS: 2.31 )
CDXS' s 10-Year Quick Ratio Range
Min: 1.07   Max: 3.75
Current: 2.31

1.07
3.75

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.90
CDXS's Price/Net Cash is ranked higher than
81% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. CDXS: 20.90 )
CDXS' s 10-Year Price/Net Cash Range
Min: 3.45   Max: 20.06
Current: 20.9

3.45
20.06
Price/Net Current Asset Value 12.10
CDXS's Price/Net Current Asset Value is ranked higher than
83% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. CDXS: 12.10 )
CDXS' s 10-Year Price/Net Current Asset Value Range
Min: 2.76   Max: 12.35
Current: 12.1

2.76
12.35
Price/Tangible Book 4.90
CDXS's Price/Tangible Book is ranked higher than
82% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. CDXS: 4.90 )
CDXS' s 10-Year Price/Tangible Book Range
Min: 1.34   Max: 4.84
Current: 4.9

1.34
4.84
Price/Median PS Value 2.50
CDXS's Price/Median PS Value is ranked higher than
70% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. CDXS: 2.50 )
CDXS' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 2.56
Current: 2.5

0.24
2.56
Forward Rate of Return (Yacktman) -104.30
CDXS's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. CDXS: -104.30 )
CDXS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 49.2   Max: 52
Current: -104.3

49.2
52

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4QK.Germany
Codexis, Inc. was incorporated in Delaware in January 2002. The Company is a developer of proprietary biocatalysts, which are enzymes or microbes that initiate or accelerate chemical reactions. The Company is currently selling its biocatalysts to customers in the pharmaceutical industry and is engaged in a multi-year research and development collaboration with Equilon Enterprises LLC dba Shell Oil Products US ('Shell') to develop advanced biofuels. The Company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals. Biocatalysts are enzymes or microbes that initiate or accelerate chemical reactions. It has focused its biocatalyst development efforts on large and rapidly growing markets, including pharmaceuticals and advanced biofuels. It has enabled biocatalyst-based drug manufacturing processes at commercial scale and has delivered biocatalysts and drug products to some of the world's pharmaceutical companies, including Dr. Reddy's Laboratories Ltd., Merck & Co., Inc., Pfizer Inc. and Ranbaxy Laboratories Limited. In the Company's research and development collaboration with Shell, it is developing biocatalysts for use in producing advanced biofuels from renewable sources of non-food plant materials, known as cellulosic biomass. It faces intense competition in the pharmaceuticals market. The Company's registered and pending U.S. trademarks include Codexis, Codex and Codex Biocatalyst Panel. The Codexis and Codexis design marks have been registered or are pending in selected foreign countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK